BACKGROUND & AIMS: Colon cancer is one of the best understood neoplasms from a genetic perspective, yet it remains the second most common cause of cancer-related death. Post-transcriptional regulation mediated by RNA-binding proteins or microRNAs coordinately targets multiple genes, holding promise involved in colon cancer initiation and development. Here we studied the role of RNA-binding protein quaking (QKI) in colon cancer. METHODS: We observed the expression pattern of QKI in normal colon and colon cancers through reverse-transcription polymerase chain reaction and Western blot. Bisulfite sequencing and methylation-specific PCR were applied for QKI promoter methylation analysis. We used enterocyte differentiation markers and soft agar assay to test the role of QKI in colon differentiation and colon cancer development. 3' Untranslated region (UTR) reporter assay and RNA-immunoprecipitation were used to confirm the interaction between QKI and beta-catenin or p27. RESULTS: QKI is significantly down-regulated and even absent in some colon cancers, which is at least partially because of the promoter hypermethylation. Forced expression of QKI in the colon cancer cells increased the expression of enterocyte differentiation marker intestinal alkaline phosphatase and lactase, together with the enhancement of p27Kip1 protein level, and membrane localized beta-catenin. Finally, QKI overexpression reduced the proliferation and tumorigenesis ability. CONCLUSIONS: Our study establishes that QKI functions as a principal regulator in the differentiation of colon epithelium and a suppressor of carcinogenesis through coordinately targeting multiple genes associated with cell growth and differentiation, whose deregulation by methylation is involved in colon cancer onset and progress. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
BACKGROUND & AIMS:Colon cancer is one of the best understood neoplasms from a genetic perspective, yet it remains the second most common cause of cancer-related death. Post-transcriptional regulation mediated by RNA-binding proteins or microRNAs coordinately targets multiple genes, holding promise involved in colon cancer initiation and development. Here we studied the role of RNA-binding protein quaking (QKI) in colon cancer. METHODS: We observed the expression pattern of QKI in normal colon and colon cancers through reverse-transcription polymerase chain reaction and Western blot. Bisulfite sequencing and methylation-specific PCR were applied for QKI promoter methylation analysis. We used enterocyte differentiation markers and soft agar assay to test the role of QKI in colon differentiation and colon cancer development. 3' Untranslated region (UTR) reporter assay and RNA-immunoprecipitation were used to confirm the interaction between QKI and beta-catenin or p27. RESULTS:QKI is significantly down-regulated and even absent in some colon cancers, which is at least partially because of the promoter hypermethylation. Forced expression of QKI in the colon cancer cells increased the expression of enterocyte differentiation marker intestinal alkaline phosphatase and lactase, together with the enhancement of p27Kip1 protein level, and membrane localized beta-catenin. Finally, QKI overexpression reduced the proliferation and tumorigenesis ability. CONCLUSIONS: Our study establishes that QKI functions as a principal regulator in the differentiation of colon epithelium and a suppressor of carcinogenesis through coordinately targeting multiple genes associated with cell growth and differentiation, whose deregulation by methylation is involved in colon cancer onset and progress. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
Authors: Pradip K Majumder; Chiara Grisanzio; Fionnuala O'Connell; Marc Barry; Joseph M Brito; Qing Xu; Isil Guney; Raanan Berger; Paula Herman; Rachel Bikoff; Giuseppe Fedele; Won-Ki Baek; Shunyou Wang; Katharine Ellwood-Yen; Hong Wu; Charles L Sawyers; Sabina Signoretti; William C Hahn; Massimo Loda; William R Sellers Journal: Cancer Cell Date: 2008-08-12 Impact factor: 31.743
Authors: Alexander Meissner; Tarjei S Mikkelsen; Hongcang Gu; Marius Wernig; Jacob Hanna; Andrey Sivachenko; Xiaolan Zhang; Bradley E Bernstein; Chad Nusbaum; David B Jaffe; Andreas Gnirke; Rudolf Jaenisch; Eric S Lander Journal: Nature Date: 2008-07-06 Impact factor: 49.962
Authors: Kai Fang; Megan Bruce; Christopher B Pattillo; Songlin Zhang; Randolph Stone; John Clifford; Christopher G Kevil Journal: Physiol Genomics Date: 2010-10-05 Impact factor: 3.107
Authors: Li-Shu Wang; Chieh-Ti Kuo; Tim H-M Huang; Martha Yearsley; Kiyoko Oshima; Gary D Stoner; Jianhua Yu; John F Lechner; Yi-Wen Huang Journal: Cancer Prev Res (Phila) Date: 2013-10-15
Authors: Takashi Shingu; Allen L Ho; Liang Yuan; Xin Zhou; Congxin Dai; Siyuan Zheng; Qianghu Wang; Yi Zhong; Qing Chang; James W Horner; Brandon D Liebelt; Yu Yao; Baoli Hu; Yiwen Chen; Gregory N Fuller; Roeland G W Verhaak; Amy B Heimberger; Jian Hu Journal: Nat Genet Date: 2016-11-14 Impact factor: 38.330
Authors: Giacomo Diaz; Marta Melis; Ashley Tice; David E Kleiner; Lopa Mishra; Fausto Zamboni; Patrizia Farci Journal: Int J Cancer Date: 2013-03-16 Impact factor: 7.396